In February 2026, the ISOLPHARM collaboration acquired, for the first time, a SPECT/CT image of 111Ag using a clinical system. The radionuclide was produced at LENA nuclear reactor in Pavia, and subsequently transported to the Arcispedale S. Maria Nuova in Reggio Emilia. Health Physics and Radiochemistry teams from this hospital and from the IRST “Dino…
Read more
On December 18th, the ISOLPHARM 2025 annual meeting took place at the Legnaro National Laboratories of INFN. The Work Packages of the SPES_MED, ADMIRAL and ISOLPHARM_CORE experiments showed their latest results according to the scheduled milestones. All presentations are available on the event’s Indico page. Thank you to all the participants!
FLUKA calculations were used to estimate the production rate of Ag-111 and other medical radionuclides at SPES. A detailed explanation is presented in a dedicated page. These calculations were published in the following papers: Andrighetto, A., Tosato, M., Ballan, M. et al. The ISOLPHARM project: ISOL-based production of radionuclides for medical applications. J Radioanal Nucl Chem 322, 73–77…
Read more
The latest achievements of the SPES-ISOLPHARM beamline were presented by Alberto Arzenton at the 16th International Conference on Heavy Ion Accelerator Technology (HIAT25), which took place at the Michigan State University (East Lansing, MI, USA) from 22nd to 27th June 2025. The content of the presentation can be found in the conference proceeding, named The…
Read more
In May 2025 the WP3 of the ADMIRAL experiment performed a characterization test of the gamma camera using Ag-111 produced at LENA, Pavia. For the first time a mouse phantom was employed to simulate the case of an in-vivo experiment. Big thanks to the LENA personnel!
We are proud to announce that the ISOLPHARM group will arrange a thematic workshop entitled ISOL technique for the production of medical radionuclides at the FisMat 2025 conference, which will take place in Venice from 7th to 11th July. Abstract Nuclear medicine is currently a field of increasing importance in the fight against cancer. The…
Read more
On December 12th, the ISOLPHARM 2024 annual meeting took place at the Legnaro National Laboratories of INFN. The Work Packages of the ADMIRAL and ISOLPHARM_CORE experiments showed their latest results according to the scheduled milestones, while the new SPES_MED experiment was kicked off. All presentations are available on the event’s Indico page. Thank you to…
Read more
The 3D scaffold bioprinting experiments for the ISOLPHARM project started at the beginning of 2024 with some geometry printing tests, where GelMa was cured under a DLP homemade printer with the main task of testing the printing resolution of the instrument. At the end of October the first test where the ink was a mixture…
Read more
In October 2024, the ISOLPHARM collaboration successfully performed the first clonogenic survival evaluation using silver-111 on cancer cells. In particular, the UMR-106 rat osteosarcoma cell line was tested. This result represents a first important experimental milestone reached by the ISOLPHARM radiobiology community, which includes groups from the Universities of Pavia (with the LENA facility), Padova,…
Read more
At the CAPiR lab of Catania a solution containing Ag-111 was injected in mice. The Bruker In-Vivo Xtreme was then used to acquire digital autoradiography images after several time points. This is the first time in which the collaboration acquires in-vivo images through the Ag-111 radiation.
